Menu Search
Equities

Briacell Therapeutics Corp

8BT:FRA

Briacell Therapeutics Corp

Actions
  • Price (EUR)1.20
  • Today's Change0.01 / 0.84%
  • Shares traded--
  • 1 Year change-77.35%
  • Beta--
Data delayed at least 15 minutes, as of Jun 20 2024 07:07 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops immunotherapies to transform cancer care. The Company’s lead drug candidate, Bria-IMT, is a cell-based patented immunotherapy that stimulates a patient’s own cancer fighting cells to attack and destroy breast cancer tumors. The Company is advancing its targeted immunotherapy program by prioritizing a Phase II clinical trial with Bria-IMT in combination with an immune checkpoint inhibitor. The Company is focused on conducting a Phase I/IIa clinical trial of Bria-IMT in a combination study with Incyte’s immune PD-1 inhibitor, retifanlimab, in advanced breast cancer. The Company is also developing Bria-OTS, an off-the-shelf personalized approach to whole cell cancer immunotherapy. The Bria-OTS immunotherapy is based on a patient’s HLA-type. Its pipeline also includes Bria-Pros, Bria-Lung, Bria-Mel and sCD80, which are in development to treat various cancers.

  • Revenue in CAD (TTM)0.00
  • Net income in CAD-8.22m
  • Incorporated2006
  • Employees5.00
  • Location
    Briacell Therapeutics Corp3rd FloorBellevue Centre,, 235-15th StrWEST VANCOUVER V7T 2X1CanadaCAN
  • Phone+1 (604) 921-1810
  • Fax+1 (604) 921-1898
  • Websitehttps://briacell.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.